Most importantly, longitudinal tracking via liquid biopsy using cfDMC revealed therapy-driven subtype conversion, such as a shift from SCLC-A to SCLC-I upon disease progression, which was accompanied by promoter methylation alterations in immune-related genes including CXCL12 (51). The gene discussed is CXCL12; the disease is small cell lung carcinoma.